The company's buffering agent is naturally drawn to the most acidic areas of the body. Since tumors actively export acid, they create a "magnet" for the therapy. This approach leverages basic chemical kinetics for targeting, bypassing the need for complex biological receptors and acting as an upstream solution.

For decades, tumor acidity was considered a mere consequence of metabolic activity (the Warburg effect). The modern understanding underpinning Dive’s strategy is that this acidity is a causal factor that actively drives tumor invasion, treatment resistance, and immune suppression, making it a viable therapeutic target.

The company's core technology was first used to buffer lactic acidosis for athletic performance. After proving they could effectively modulate pH, they asked "where does pH matter most biologically?" This led them to the long-understood but hard-to-drug problem of the acidic tumor microenvironment, a much larger market.

Eupraxia's technology is defined by its precision: delivering a stable, flat dose directly into target tissue for up to a year. This hyper-local approach mimics the stability of a continuous IV infusion, aiming to maximize efficacy while minimizing systemic side effects caused by the 'peaks and troughs' of conventional pills or injections.

Current solid TKI pills, especially capsules, make fine-tuned dose adjustments difficult. A liquid formulation would offer crucial flexibility, allowing for precise dosing (e.g., 350mg instead of 400mg) to manage the dose-response relationship. It would also be ideal for patients with feeding tubes or GI issues who cannot tolerate or swallow solid pills, preventing treatment delays.

An oral FGFR inhibitor (ARDA) showed strong efficacy but was halted due to severe systemic toxicities. This "failure" successfully provided proof of concept for the drug's mechanism, strategically redirecting research toward local, in-bladder delivery to maintain efficacy while minimizing side effects.

Instead of going directly into high-risk oncology trials, Dive validated its core mechanism—systemic pH modulation via a topical agent—in a 98-patient gout study. This provided human data on target engagement and safety, significantly de-risking its subsequent, more complex cancer program by answering a key question upfront.

While most immuno-oncology drugs target specific cellular pathways, Dive Biosciences targets the acidic tumor microenvironment itself. This is framed as a foundational "upstream checkpoint" that degrades the entire immune "ecology," suppressing every type of immune cell in the tumor's vicinity at once, rather than one receptor at a time.

Resvita's CTO joined because the company first solved the difficult challenge of delivering proteins to the skin. This created a 'plug-and-play' platform that he calls a 'protein designer's dream.' By abstracting away the delivery problem, the team can focus solely on designing the optimal therapeutic protein for each disease.